
    
      This is a randomized, open-label, crossover study during which each participant receives a
      single injection of rFVIIIFc from 2 different vial concentrations (PK assessment). After the
      PK assessment, participants are provided with rFVIIIFc for either prophylactic or episodic
      (on-demand) treatment for up to 6 months.
    
  